

ABSTRACT

THE REIMBURSEMENT OF COST IN THE ADOPTION OF UNIVERSAL LEUKO-REDUCTION

This study examined the influence of reimbursement as a cost factor in the adoption of universal leuko-reduction of cellular products in independent blood banks located in the United States. To examine this effect, three variables of cost were tested. The variables were size of blood center, location of hospital customers, rural or urban, and size of hospitals being served by these blood centers. To test these variables a research instrument was created and sent to quality assurance managers/directors of blood centers. The blood centers surveyed were all members of America's Blood Centers. The results were analyzed using Statistical Package for Social Sciences (SPSS) to determine the significance of the three hypotheses tested. Significance was defined at .05. The results supported the null hypothesis; consequently, according to this study, reimbursement of cost was not conclusively proven to be a significant factor in the adoption of universal leuko-reduction.

Constance Mollo
August 2003